Loss of PEDF: A Novel Mechanism of Antihormone Resistance in Breast Cancer

Abstract

Resistance to endocrine therapy such as tamoxifen or aromatase inhibitors is a major clinical obstacle to the effective treatment and cure of women with estrogen receptor (ER)-positive breast cancer. It is estimated that ~40% of breast cancer patients will develop endocrine-resistant disease following long-term treatment. The possibility of identifying new targets for therapy in resistant disease, or patients, who may benefit from additional treatment with existing therapies, provides a strong impetus to identify markers and mediators of therapeutic resistance. Our laboratory has identified a novel protein called pigment epithelium derived factor (PEDF) that appears to be suppressed/silenced in endocrine resistant breast cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2015
Accession Number
AD1004089

Entities

People

  • Joan Lewis-Wambi

Organizations

  • University of Kansas Medical Center

Tags

DTIC Thesaurus Topics

  • Breast Cancer
  • Cell Physiological Processes
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Health Services
  • Peptide Growth Factors
  • Proteins

Readers

  • Breast cancer cell signaling and growth regulation.
  • Oncology (Cancer Research).